GB9304745D0 - Use of pharmaceutical formulations - Google Patents

Use of pharmaceutical formulations

Info

Publication number
GB9304745D0
GB9304745D0 GB939304745A GB9304745A GB9304745D0 GB 9304745 D0 GB9304745 D0 GB 9304745D0 GB 939304745 A GB939304745 A GB 939304745A GB 9304745 A GB9304745 A GB 9304745A GB 9304745 D0 GB9304745 D0 GB 9304745D0
Authority
GB
United Kingdom
Prior art keywords
pharmaceutical formulations
formulations
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB939304745A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncholab AB
Original Assignee
Oncholab AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncholab AB filed Critical Oncholab AB
Priority to GB939304745A priority Critical patent/GB9304745D0/en
Publication of GB9304745D0 publication Critical patent/GB9304745D0/en
Priority to AU61477/94A priority patent/AU6147794A/en
Priority to JP6519734A priority patent/JPH08509961A/en
Priority to EP94908435A priority patent/EP0688229A1/en
Priority to SG1996000120A priority patent/SG42848A1/en
Priority to CA002157761A priority patent/CA2157761A1/en
Priority to PCT/GB1994/000432 priority patent/WO1994020145A1/en
Priority to NZ262160A priority patent/NZ262160A/en
Priority to ZA941651A priority patent/ZA941651B/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1275—Lipoproteins; Chylomicrons; Artificial HDL, LDL, VLDL, protein-free species thereof; Precursors thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
GB939304745A 1993-03-09 1993-03-09 Use of pharmaceutical formulations Pending GB9304745D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GB939304745A GB9304745D0 (en) 1993-03-09 1993-03-09 Use of pharmaceutical formulations
AU61477/94A AU6147794A (en) 1993-03-09 1994-03-07 Use of low density lipoprotein with cytotoxic substances
JP6519734A JPH08509961A (en) 1993-03-09 1994-03-07 Use of low density lipoproteins and cytotoxic agents
EP94908435A EP0688229A1 (en) 1993-03-09 1994-03-07 Use of low density lipoprotein with cytotoxic substances
SG1996000120A SG42848A1 (en) 1993-03-09 1994-03-07 Use of low density lipoprotein with cytotoxic substances
CA002157761A CA2157761A1 (en) 1993-03-09 1994-03-07 Use of low density lipoprotein with cytotoxic substances
PCT/GB1994/000432 WO1994020145A1 (en) 1993-03-09 1994-03-07 Use of low density lipoprotein with cytotoxic substances
NZ262160A NZ262160A (en) 1993-03-09 1994-03-07 Anticancer drug with cytotoxic substance formulated with a low density 1ipoprotein
ZA941651A ZA941651B (en) 1993-03-09 1994-03-09 Use of low density lipoprotein with cytotoxic substances

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939304745A GB9304745D0 (en) 1993-03-09 1993-03-09 Use of pharmaceutical formulations

Publications (1)

Publication Number Publication Date
GB9304745D0 true GB9304745D0 (en) 1993-04-28

Family

ID=10731686

Family Applications (1)

Application Number Title Priority Date Filing Date
GB939304745A Pending GB9304745D0 (en) 1993-03-09 1993-03-09 Use of pharmaceutical formulations

Country Status (9)

Country Link
EP (1) EP0688229A1 (en)
JP (1) JPH08509961A (en)
AU (1) AU6147794A (en)
CA (1) CA2157761A1 (en)
GB (1) GB9304745D0 (en)
NZ (1) NZ262160A (en)
SG (1) SG42848A1 (en)
WO (1) WO1994020145A1 (en)
ZA (1) ZA941651B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU761844C (en) * 1998-11-09 2004-09-23 F. Hoffmann-La Roche Ag Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
ES2333400T3 (en) * 1999-04-01 2010-02-22 Hana Biosciences, Inc. COMPOSITIONS AND PROCEDURES TO TREAT LYMPHONES.
AU2013347990B2 (en) 2012-11-20 2018-01-18 Arbutus Biopharma Corp. Improved method for the preparation of liposome encapsulated vincristine for therapeutic use
TWI678213B (en) 2015-07-22 2019-12-01 美商史倍壯製藥公司 A ready-to-use formulation for vincristine sulfate liposome injection
WO2017187343A2 (en) * 2016-04-29 2017-11-02 Thome Kreutz Fernando Nanoemulsions and methods for cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0105404A1 (en) * 1982-09-30 1984-04-18 Merck & Co. Inc. Derivatives of steroid compounds linked to cyotoxic agents and process for their preparation

Also Published As

Publication number Publication date
JPH08509961A (en) 1996-10-22
EP0688229A1 (en) 1995-12-27
AU6147794A (en) 1994-09-26
CA2157761A1 (en) 1994-09-15
WO1994020145A1 (en) 1994-09-15
NZ262160A (en) 1997-05-26
ZA941651B (en) 1995-09-11
SG42848A1 (en) 1997-10-17

Similar Documents

Publication Publication Date Title
SG55163A1 (en) Pharmaceutical formulations
ZA921093B (en) Pharmaceutical formulations
GB9323399D0 (en) Pharmaceutical formulations
GB9311030D0 (en) Pharmaceutical formulations
GB9201639D0 (en) Pharmaceutical formulations
GB9304745D0 (en) Use of pharmaceutical formulations
GB9222849D0 (en) Novel use of pharmaceutical compositions
GB9304800D0 (en) Pharmaceutical formulations
GB9321676D0 (en) Pharmaceutical formulations
GB9315119D0 (en) Pharmaceutical formulations
GB9314443D0 (en) Pharmaceutical formulations
GB9312344D0 (en) Pharmaceutical formulations
GB9301250D0 (en) Pharmaceutical formulations
GB9304799D0 (en) Pharmaceutical formulations
GB9304797D0 (en) Pharmaceutical formulations
GB9302908D0 (en) Pharmaceutical formulations
GB9203212D0 (en) Pharmaceutical formulations
GB9307003D0 (en) Pharmaceutical formulations
GB9217602D0 (en) Pharmaceutical formulations
GB9207338D0 (en) Pharmaceutical formulations
GB9204774D0 (en) Pharmaceutical formulations
GB9221244D0 (en) Pharmaceutical formulations
GB9221694D0 (en) Pharmaceutical formulation
GB9212968D0 (en) Pharmaceutical formulation
GB9305437D0 (en) Pharmaceutical formulation